Haemophilia

Blood in a Petri dish
#Clinical trial #CSL #Haemophilia

Results confirm safety and durability of haemophilia drug 

Results from a Phase III trial have confirmed the durability and safety of a one-time infusion to treat adults living with moderate to severe haemophilia B.  Etranacogene dezaparvovec, developed by global biopharma company CSL, was studied in a Phase III open-label, single-dose, single-arm trial, with 54 male participants… Read More

#News

Blood cells
#CSL Behring #Early access #Gene therapy #Haematology #Haemophilia

First patient receives gene therapy for haemophilia B in Germany

CSL Behring Germany has announced that the first haemophilia B patient in Germany was treated with the gene therapy Hemgenix (etranacogene dezaparvovec) at the Hemophilia Treatment Center at Hannover Medical School. Hemgenix is the first one-time gene therapy approved in Europe for the treatment of adults with severe… Read More

#News

Haemophilia
#Cell and gene therapy #Gene therapy #Haemophilia #University College London

Haemophilia gene therapy patients thriving a decade later

Patients who received a one-off gene therapy to treat haemophilia are still doing well up to 13 years later, finds a new study from researchers at University College London (UCL), the Royal Free Hospital and St Jude Children’s Research Hospital, Tennessee.  The study,… Read More

#Editor's Choice #News

Cell and gene therapy concept
#CSL Behring #Drug discovery #Gene therapy #Haemophilia

Gene therapy landmark in haemophilia B

Following the news that the first patients in Denmark with haemophilia B had been treated with Hemgenix (etranacogene dezaparvovec) gene therapy since European Commission approval, DDW’s Megan Thomas spoke with Dr Fredrik Sjöö, Head of Medical Affairs in the Nordic Region at CSL Behring, as well as Radovan Tomic, Global Market Access Director… Read More

#Exclusive Content

Gene therapy for haemophilia
#CSL #Gene therapy #Haemophilia #Scottish Medicines Consortium (SMC)

First gene therapy for haemophilia B accepted in Scotland

The Scottish Medicines Consortium (SMC) has accepted CSL Behring’s Hemgenix (etranacogene dezaparvovec) for use within NHS Scotland on an interim basis, until full marketing authorisation is granted. The single infusion gene therapy is recommended for adults with severe or moderately severe haemophilia B without a history of FIX inhibitors. The… Read More

#News #Regulatory

Woman with a nose bleed
#Bispecific Antibodies #Events #Haemophilia #Novo Nordisk #Phase III trial

Bispecific antibody successfully reduced bleeds in haemophilia A

Novo Nordisk has announced results from the Phase III FRONTIER2 trial of 254 adults and adolescents aged 12 years and over with haemophilia A, with and without inhibitors. The trial assessed both once-weekly and once-monthly prophylactic treatment with the investigational treatment Mim8. The data… Read More

#News

#AAV #AskBio #Duchenne muscular dystrophy #Gene editing #Giant axonal neuropathy #Haemophilia #Pompe disease

Podcast: The evolution and future of gene therapy

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dr… Read More

#News

Haemophilia
#CSL #Gene therapy #Haemophilia #National Institute for Health and Care Excellence (NICE)

UK health watchdog rejects gene therapy for haemophilia B

In a draft guidance consultation, the UK National Institute for Health and Care Excellence (NICE) has decided not to recommend the use of Hemgenix (etranacogene dezaparvovec) on the NHS for treating haemophilia B (congenital factor IX deficiency). Although the gene therapy was granted a marketing authorisation by the UK Medicines… Read More

#News #Regulatory #Trending News

#BioMarin Pharmaceuticals #Cell and gene therapy #FDA #Gene therapy #Haemophilia

One-time gene therapy for haemophilia A gets FDA green light

The US Food and Drug Administration (FDA) has approved the first gene therapy for adults with severe haemophilia A. BioMarin’s Roctavian (valoctocogene roxaparvovec-rvox) has been approved for the treatment of adults with severe haemophilia A (congenital factor VIII (FVIII) deficiency with FVIII activity < 1 IU/dL) without antibodies to adeno-associated… Read More

#News #Regulatory #Trending News

Haematology
#Cell and gene therapy #CSL #Gene therapy #Haemophilia #MHRA #Phase III trial

First gene therapy for haemophilia B approved in Great Britain

CSL’s Hemgenix (etranacogene dezaparvovec) has been authorised as the first gene therapy for adults with severe and moderately severe haemophilia B (congenital Factor IX (FIX) deficiency) in Great Britain. It has been granted a marketing authorisation for patients without a history of FIX inhibitors by the UK Medicines and Healthcare… Read More

#News #Regulatory

Woman bleeding from the nose
#CHMP #CSL #Europe #European Commission #Haemophilia #Marketing approval authorisation

EU-approved gene therapy reduced haemophilia bleeds by 64%

The European Commission has granted conditional marketing authorisation for CSL’s Hemgenix (etranacogene dezaparvovec), the first one-time gene therapy for severe and moderately severe haemophilia B (congenital Factor IX deficiency) in adults without a history of Factor IX inhibitors.   In an ongoing clinical trial, the drug reduced the… Read More

#Editor's Choice #News

Blood in a Petri dish
#BioMarin Pharmaceuticals #Cell and gene therapy #Gene therapy #Haemophilia #Orphan drugs #Phase III trial

Haemophilia one-time gene therapy effective for three years

An investigational one-time gene therapy for the treatment of adults with severe haemophilia A has been proven to be effective for more than three years from treatment.  BioMarin Pharmaceutical revealed the positive results from its ongoing global Phase III GENEr8-1 study of Roctavian (valoctocogene roxaparvovec).  … Read More

#News #Trending News

Gene therapy for haemophilia
#Cell and gene therapy #CHMP #CSL #Europe #Gene therapy #Haemophilia

First gene therapy for haemophilia B gets go ahead in Europe

The first gene therapy for haemophilia B could soon be available to patients in Europe following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).  The CHMP has recommended conditional marketing authorisation of CSL’s etranacogene dezaparvovec, a one-time gene therapy for the treatment of appropriate adults… Read More

#News #Regulatory #Trending News

#Cancer research #Diabetes #Drug development #Drug discovery #FDA #Gene therapy #Haemophilia #MHRA #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders

News update available on DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  Gene therapies have made the headlines over the last week, with treatments… Read More

#News

#Cancer research #Diabetes #Drug development #Drug discovery #FDA #Gene therapy #Haemophilia #MHRA #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders

This week in drug discovery (21-25 November)

News round-up for 21-25 November by DDW Digital Content Editor Diana Spencer  Gene therapies have made the headlines over the last few days, with treatments for rare AADC deficiency, lung cancer and haemophilia B given the go ahead from regulators. This week has also seen the first… Read More

#News

#Cell and gene therapy #FDA #Gene therapy #Haemophilia #Regulatory

FDA approves first gene therapy for haemophilia B

The US Food and Drug Administration (FDA) has approved Hemgenix (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy for appropriate adults with haemophilia B.   The drug is approved for the treatment of adults with haemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening… Read More

#News #Regulatory